The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
 
Minke Smits
No Relationships to Disclose
 
Harm Westdorp
No Relationships to Disclose
 
Mark A.J. Gorris
No Relationships to Disclose
 
Thomas van Ee
No Relationships to Disclose
 
Tjitske Duiveman-de Boer
No Relationships to Disclose
 
Kiek Verrijp
No Relationships to Disclose
 
Jennifer C Jones
Patents, Royalties, Other Intellectual Property - Intellectual property relating to nanoFACS, targeted immune adjuvants in combination with cytotoxic immunotherapies, and EV subset detection filed or pending by Stanford University, DFCI, and NIH/NCI 2010-2016. No royalties received by the speaker.
Other Relationship - Beckman Coulter/NIH
 
Inge M. van Oort
No Relationships to Disclose
 
Michiel Sedelaar
No Relationships to Disclose
 
Antoine Van Der Heijden
No Relationships to Disclose
 
Alfred Witjes
Consulting or Advisory Role - BioCancell; Cepheid; MEL Pharma; Nucleix; Spectrum Pharmaceuticals; taris
Research Funding - cepheid (Inst); Nucleix (Inst); taris (Inst)
 
Astrid Eijkelenboom
No Relationships to Disclose
 
Marjolijn Ligtenberg
No Relationships to Disclose
 
Katrien Grunberg
No Relationships to Disclose
 
Johannes C Textor
No Relationships to Disclose
 
Jack A. Schalken
No Relationships to Disclose
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst)
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Merck Sharp & Dohme
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Sharp & Dohme
 
Jolanda De Vries
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Bayer; Janssen-Cilag; Sanofi/Aventis